Release Details

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:

• Guggenheim’s 2^nd Annual Healthcare Innovation Conference
  Forum: Fireside Chat
  Date: Monday, November 10, 2025
  Time: 10:30 a.m. ET

• Stifel 2025 Healthcare Conference
  Forum: Corporate Presentation
  Date: Wednesday, November 12, 2025
  Time: 10:40 a.m. ET

• Jefferies London Healthcare Conference
  Forum: 1x1 Investor Meetings
  Date: Monday, November 17, 2025

A live webcast and subsequent archived replay of each presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU^™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E^™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with data anticipated in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema (DME) is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901 (vorolanib intravitreal insert). DURAVYU is an investigational medicinal product and is not authorized for sale in any country at the present time. FDA approval in the United States and marketing authorization in any other country and the timeline for potential approval or authorization is uncertain.

Investors:

Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

Source: EyePoint Pharmaceuticals, Inc.